[Neuroplasticity and Parkinson disease]

Rev Neurol (Paris). 2002 Dec:158 Spec no 1:S42-8.
[Article in French]

Abstract

Emerging concept, to date, neuroplasticity becomes a concrete reality in the adult central nervous system (CNS), particularly in a so-called neurodegenerative disease as idiopathic Parkinson's disease (IPD). After a brief survey of some general aspects of plasticity in the CNS, the present tutorial review illustrates with recent data from the literature the modes of plastic changes during the course of IPD, either resulting from dopaminergic denervation (hyperactivity of remaining dopaminergic neurons with increase of their excitatory cholinergic innervation in the substantia nigra, enhancement of the corticostriatal glutamatergic synaptic activity at the striatal level) or due to dopaminergic treatment (change in phosphorylation state of the striatal glutamate receptors, internalization of D1 Dopamine receptors). Neuroplasticity in Parkinson's disease could represent a rational basis for forthcoming therapeutic issues.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Antiparkinson Agents / therapeutic use
  • Humans
  • Levodopa / therapeutic use
  • Neuronal Plasticity*
  • Parkinson Disease / drug therapy
  • Parkinson Disease / pathology*

Substances

  • Antiparkinson Agents
  • Levodopa